Structure, development, preclinical and clinical efficacy of blinatumomab in acute lymphoblastic leukemia.

IF 3 4区 医学 Q2 ONCOLOGY
Future oncology Pub Date : 2015-01-01 DOI:10.2217/fon.15.84
Naresh Bumma, Nikolaos Papadantonakis, Anjali S Advani
{"title":"Structure, development, preclinical and clinical efficacy of blinatumomab in acute lymphoblastic leukemia.","authors":"Naresh Bumma,&nbsp;Nikolaos Papadantonakis,&nbsp;Anjali S Advani","doi":"10.2217/fon.15.84","DOIUrl":null,"url":null,"abstract":"<p><p>The treatment of acute lymphoblastic leukemia (ALL) in adults remains challenging and novel therapies are needed. The antigen, CD19, is expressed by >90% of pre-B ALLs and represents an attractive therapeutic target. The bispecific T-cell-engaging antibody, blinatumomab, targets CD19 and has demonstrated encouraging results in minimal residual disease positive and relapsed/refractory pre-B ALL. In this review, we discuss in detail the mechanism of action and key pharmacologic aspects of blinatumomab. In addition, the preclinical studies, clinical studies and toxicities are summarized.</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":null,"pages":null},"PeriodicalIF":3.0000,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/fon.15.84","citationCount":"11","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2217/fon.15.84","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 11

Abstract

The treatment of acute lymphoblastic leukemia (ALL) in adults remains challenging and novel therapies are needed. The antigen, CD19, is expressed by >90% of pre-B ALLs and represents an attractive therapeutic target. The bispecific T-cell-engaging antibody, blinatumomab, targets CD19 and has demonstrated encouraging results in minimal residual disease positive and relapsed/refractory pre-B ALL. In this review, we discuss in detail the mechanism of action and key pharmacologic aspects of blinatumomab. In addition, the preclinical studies, clinical studies and toxicities are summarized.

blinatumumab治疗急性淋巴细胞白血病的结构、发展、临床前及临床疗效。
成人急性淋巴细胞白血病(ALL)的治疗仍然具有挑战性,需要新的治疗方法。抗原CD19在90%以上的b前all细胞中表达,是一个有吸引力的治疗靶点。双特异性t细胞结合抗体blinatumomab靶向CD19,并在最小残留病阳性和复发/难治性前b ALL中显示出令人鼓舞的结果。在这篇综述中,我们详细讨论了blinatumomab的作用机制和关键的药理学方面。并对其临床前研究、临床研究及毒性进行了综述。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Future oncology
Future oncology ONCOLOGY-
CiteScore
5.40
自引率
3.00%
发文量
335
审稿时长
4-8 weeks
期刊介绍: Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community. The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.
文献相关原料
公司名称 产品信息 采购帮参考价格
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信